Drug trial results and the stock moves that follow

11 resultsBig movers (±10%+)
Met endpoint

Tabirafusp tedromer

Phase 3 n=675 Wet Age-related Macular Degeneration

Kodiak Sciences KOD

24h stock move +168.93%
Met endpoint

barzolvolimab

Phase 3 n=963 Chronic Spontaneous Urticaria

Celldex CLDX

24h stock move −11.59%
Met endpoint

Mosliciguat

Phase 2 n=135 Pulmonary Hypertension

Roivant ROIV

24h stock move +18.75%
Missed endpoint

Envudeucitinib

Phase 2 n=408 SLE

Alumis ALMS

24h stock move −54.05%
Met endpoint

Avexitide

Phase 3 n=75 Post Bariatric Hypoglycemia

Amylyx Pharmaceuticals AMLX

24h stock move +66.59%
Met endpoint

NEO100

Phase 2 Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies NTHI

24h stock move −20.91%
Met endpoint

Divesiran

Phase 2

Silence Therapeutics SLN

24h stock move +30.88%
Missed endpoint

TNX-103

Phase 3 n=230 Pulmonary Hypertension

Tenax Therapeutics TENX

24h stock move −89.29%
Met endpoint

ML-007C

Phase 2 Schizophrenia

MapLight Therapeutics MPLT

24h stock move −73.66%

Daily roundups

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.